Show simple item record

dc.contributor.authorKaymakoglu, Sabahattin
dc.contributor.authorAkyuz, Filiz
dc.contributor.authorIliaz, Raim
dc.contributor.authorKoksalan, Kaya
dc.contributor.authorOnder, Semen
dc.contributor.authorCavus, Bilger
dc.contributor.authorDemir, Kadir
dc.contributor.authorBesisik, Fatih
dc.contributor.authorGulluoglu, Mine
dc.contributor.authorEvirgen, Sami
dc.contributor.authorKaraca, Cetin
dc.contributor.authorCagatay, Tulin
dc.contributor.authorKeskin, Metin
dc.contributor.authorSoyer, Ozlem M.
dc.contributor.authorOrmeci, Asli
dc.date.accessioned2021-03-05T16:39:08Z
dc.date.available2021-03-05T16:39:08Z
dc.date.issued2019
dc.identifier.citationAkyuz F., Cavus B., Iliaz R., Soyer O. M. , Ormeci A., Evirgen S., Onder S., Koksalan K., Keskin M., Karaca C., et al., "Inflammatory bowel disease and mycobacteria: How much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?", European Journal of Gastroenterology and Hepatology, cilt.31, sa.7, ss.777-780, 2019
dc.identifier.issn0954-691X
dc.identifier.othervv_1032021
dc.identifier.otherav_c1a3de70-8634-40bb-a994-da9f3c0dff9b
dc.identifier.urihttp://hdl.handle.net/20.500.12627/128526
dc.identifier.urihttps://doi.org/10.1097/meg.0000000000001403
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067011546&origin=inward
dc.description.abstractObjectives Isoniazid (INH) prophylaxis is recommended for the prevention of tuberculosis (TB) reactivation before or/and during initiation of treatment with tumour necrosis factor antagonists (anti-TNF agents). Nonetheless, the long-term effectiveness of chemoprophylaxis is not clear. In this study, we aimed to evaluate the characteristics of patients who developed TB reactivation in spite of INH prophylaxis associated with anti-TNF treatment. Patients and methods In this retrospective study, medical records of 1263 patients with inflammatory bowel disease were reviewed. Baseline TB screening tests (purified protein derivative test and/or QuantiFERON-TB Gold test) were performed on all patients before initiation of anti-TNF therapy. Patients with purified protein derivative of more than 5 mm and/or a positive result of the QuantiFERON-TB Gold test received INH prophylaxis for 9 months. We analysed the data of patients diagnosed with TB reactivation during the anti-TNF treatment despite INH chemoprophylaxis. Results Overall, 175 patients underwent anti-TNF treatment. Sixty of these 175 patients had pretreatment testing showing latent TB infection and therefore were treated concomitantly with INH for 9 months in addition to their anti-TNF treatment. TB reactivation occurred in four of these 60 co-INH/anti-TNF treated patients. Active TB was diagnosed after 37.5 +/- 27 (range: 18-84) months of anti-TNF treatment. In two of the four patients that active TB was diagnosed, was also detected other Mycobacterium spp.: M. bovis in one patient and M. genavense in the other one. Conclusion INH chemoprophylaxis may not prevent the reactivation of TB during anti-TNF therapy in the long-term. Patients should be carefully and periodically screened for TB reactivation during anti-TNF therapy.
dc.language.isoeng
dc.subjectGASTROENTEROLOJİ VE HEPATOLOJİ
dc.subjectGastroenteroloji-(Hepatoloji)
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.titleInflammatory bowel disease and mycobacteria: How much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
dc.typeMakale
dc.relation.journalEuropean Journal of Gastroenterology and Hepatology
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume31
dc.identifier.issue7
dc.identifier.startpage777
dc.identifier.endpage780
dc.contributor.firstauthorID265432


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record